India has a significant opportunity to lead in the transition from generics to biologics by focusing on building capacity for next-generation biologic modalities and securing access to essential inputs. Biologics such as cell and gene therapies, monoclonal antibodies, antibody-drug conjugates, and nucleic acid-based treatments rely on a complex array of components like expression vectors, engineered cell lines, and purification reagents. Ensuring a steady supply of these components near biomanufacturing hubs is crucial for supply security, operational resilience, cost reduction, and accelerated development timelines. This strategy not only boosts national self-reliance but also positions India as an attractive destination for global partners seeking to diversify away from high-risk regions.
Read more from hindustantimes.com
